TY - JOUR
T1 - Time in therapeutic range for targeted temperature management and outcomes following out-of-hospital cardiac arrest
AU - Wheelock, Kevin M.
AU - Chan, Paul S.
AU - Chen, Lian
AU - de Lemos, James A.
AU - Miller, P. Elliott
AU - Nallamothu, Brahmajee K.
AU - Girotra, Saket
AU - Khera, Rohan
N1 - Funding Information:
This study was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under the award K23HL153775. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
Dr Khera receives support from the Doris Duke Charitable Foundation (under award, 2022060 ). He also receives research support, through Yale, from Bristol-Myers Squibb. He is a coinventor of U.S. Provisional Patent Applications 63/177 ,117 and 63/346 ,610, unrelated to current work. He is also a founder of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. The other authors have no relevant disclosures.
Funding Information:
Dr Khera receives support from the Doris Duke Charitable Foundation (under award, 2022060). He also receives research support, through Yale, from Bristol-Myers Squibb. He is a coinventor of U.S. Provisional Patent Applications 63/177,117 and 63/346,610, unrelated to current work. He is also a founder of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. The other authors have no relevant disclosures.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2023/1
Y1 - 2023/1
N2 - Objective: For comatose survivors of out-of-hospital cardiac arrest (OHCA), current guidelines recommend targeted temperature management (TTM) with a goal temperature of 32 °C–36 °C for at least 24 h. We examined adherence to temperature targets, quantified as time-in-therapeutic range (TTR), and association of TTR with survival and neurologic outcomes. Methods: We conducted a retrospective cohort study of the Resuscitation Outcomes Consortium-Continuous Chest Compressions trial, including adults with OHCA who underwent TTM for >12 h. We imputed continuous temperatures between consecutive temperature measurements using the linear interpolation method and calculated TTR for multiple target temperatures. The association of TTR with survival to hospital discharge and favorable neurological outcome was evaluated using hierarchical regression models. Main results: Among 2,637 patients (mean age 62.3 years, 29.9 % female), the median duration of TTR for TTM between 32 °C–36 °C was 23 (IQR: 21–24) hours with a median time outside therapeutic range of 0.9 (IQR: 0.0–4.2) hours. In risk-adjusted analyses, there was no association of TTR of 32 °C–36 °C with overall survival (OR 1.00 [95 % CI, 0.90–1.10]) or favorable neurologic outcome (1.02 [95 % CI, 0.90–1.14]). However, in assessments of TTR 33 °C–36 °C, there was a significant association with favorable neurologic survival (OR 1.12 [1.01–1.25]) but not overall survival (OR 1.04 [0.94–1.15]). Conclusions: Among patients with OHCA who underwent TTM, we found variability in adherence to guideline-recommended treatment targets. Higher TTR was not associated with overall survival, but for certain temperature thresholds, TTR was associated with favorable neurologic outcome.
AB - Objective: For comatose survivors of out-of-hospital cardiac arrest (OHCA), current guidelines recommend targeted temperature management (TTM) with a goal temperature of 32 °C–36 °C for at least 24 h. We examined adherence to temperature targets, quantified as time-in-therapeutic range (TTR), and association of TTR with survival and neurologic outcomes. Methods: We conducted a retrospective cohort study of the Resuscitation Outcomes Consortium-Continuous Chest Compressions trial, including adults with OHCA who underwent TTM for >12 h. We imputed continuous temperatures between consecutive temperature measurements using the linear interpolation method and calculated TTR for multiple target temperatures. The association of TTR with survival to hospital discharge and favorable neurological outcome was evaluated using hierarchical regression models. Main results: Among 2,637 patients (mean age 62.3 years, 29.9 % female), the median duration of TTR for TTM between 32 °C–36 °C was 23 (IQR: 21–24) hours with a median time outside therapeutic range of 0.9 (IQR: 0.0–4.2) hours. In risk-adjusted analyses, there was no association of TTR of 32 °C–36 °C with overall survival (OR 1.00 [95 % CI, 0.90–1.10]) or favorable neurologic outcome (1.02 [95 % CI, 0.90–1.14]). However, in assessments of TTR 33 °C–36 °C, there was a significant association with favorable neurologic survival (OR 1.12 [1.01–1.25]) but not overall survival (OR 1.04 [0.94–1.15]). Conclusions: Among patients with OHCA who underwent TTM, we found variability in adherence to guideline-recommended treatment targets. Higher TTR was not associated with overall survival, but for certain temperature thresholds, TTR was associated with favorable neurologic outcome.
KW - cardiac arrest
KW - outcomes
KW - targeted temperature management
KW - therapeutic hypothermia
KW - time in therapeutic range
UR - http://www.scopus.com/inward/record.url?scp=85144774288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144774288&partnerID=8YFLogxK
U2 - 10.1016/j.resuscitation.2022.11.016
DO - 10.1016/j.resuscitation.2022.11.016
M3 - Article
C2 - 36442596
AN - SCOPUS:85144774288
SN - 0300-9572
VL - 182
JO - Resuscitation
JF - Resuscitation
M1 - 109650
ER -